Register Now!

Wednesday, March 31 - Friday, April 2, 2027

In-Person Symposium
Irvine Auditorium
3401 Spruce Street
Philadelphia, PA 19104

Overview

Penn Medicine and Children’s Hospital of Philadelphia continue to advance the science and clinical application of cell and gene therapies, reinforcing Philadelphia’s role as “Cellicon Valley.” The 2027 symposium will convene leading experts to examine advances in CAR T-cell therapy, in vivo platforms, and precision cell engineering across a broad range of malignant and nonmalignant diseases.

Plenary sessions will examine emerging evidence, therapeutic strategies, and the policy landscape. Concurrent sessions will provide focused content tailored to the educational needs of clinicians, nurses, researchers, and industry leaders. Interactive discussions will integrate scientific, clinical, and patient perspectives on treatment delivery, commercialization, access, and survivorship.

Target Audience

This symposium is intended for adult and pediatric hematologists, oncologists, transplant specialists, clinical immunologists, rheumatologists, neurologists, transfusion medicine specialists, nurses, pharmacists, advanced practice providers, researchers, fellows and other trainees, industry professionals, healthcare administrators, policy and reimbursement professionals, patients, caregivers, family members, advocates, and members of the public interested in advances in cell and gene therapies.

Learning Objectives

Upon completion of this symposium, participants should be able to:

  • Compare in vivo and ex vivo cell and gene therapy platforms.
  • Describe advances in precision cell engineering for individualized therapies.
  • Evaluate emerging CAR T-cell applications in autoimmune and neurologic diseases.
  • Compare CAR T-cell therapy, stem cell transplantation, and bispecific antibodies for multiple myeloma.
  • Assess therapeutic advances for sickle cell disease and thalassemia.
  • Explain key considerations in cell collection, mobilization, and manufacturing.
  • Describe medical and nursing care for adult and pediatric patients.
  • Interpret long-term CAR T-cell outcomes and implications for follow-up and survivorship.
  • Evaluate access strategies incorporating patient perspectives, advocacy, and reimbursement models.
  • Analyze how policy, infrastructure, and commercialization affect therapy development and delivery.

For additional information, please contact Gabrielle White.